An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) will participate in the 42nd annual J.P. Morgan Healthcare Conference. Ying Huang, Ph.D., the company’s CEO, will deliver the presentation on Tuesday, January 9, 2024, at 2:15 p.m. PT. The live audio webcast will be available on Legend’s website.
Positive
None.
Negative
None.
SOMERSET, N.J.--(BUSINESS WIRE)--
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the 42nd annual J.P. Morgan Healthcare Conference in San Francisco, CA. Ying Huang, Ph.D., the company’s chief executive officer, will deliver the company presentation on Tuesday, January 9, 2024, at 2:15 p.m. PT.
The live audio webcast will be available to investors and other interested parties by accessing the Investor Relationssection of Legend’s website. The audio webcast replay will be available approximately 48-hrs after the webcast.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
What is Legend Biotech Corporation's ticker symbol?
The ticker symbol for Legend Biotech Corporation is LEGN.
When will the CEO of Legend Biotech Corporation deliver the company presentation at the J.P. Morgan Healthcare Conference?
Ying Huang, Ph.D., the CEO of Legend Biotech Corporation, will deliver the company presentation on Tuesday, January 9, 2024, at 2:15 p.m. PT.
Where can investors access the live audio webcast of Legend Biotech Corporation's presentation at the conference?
Investors and other interested parties can access the live audio webcast by visiting the Investor Relations section of Legend Biotech Corporation's website.
When will the audio webcast replay of Legend Biotech Corporation's presentation be available?
The audio webcast replay will be available approximately 48 hours after the webcast.
Legend Biotech Corporation American Depositary Shares
legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated a strong pipeline of chimeric antigen receptor(car) product candidates to treat a wide variety of liquid and solid tumors. our ambition to succeed in the cars field has been substantially fulfilled by the latest clinical trial results that we have achieved a great clinical success in treating multiple myeloma, a previously incurable blood cancer. by applying one of our proprietary car-t technology, we have reached a promising result in the clinical research for the enrolled patient group bearing refractory and relapsed multiple myeloma. legend biotech corporation is founded on the vision that the previous incurable previousincurable cancer will be safely and effectively treated with fine-tuning products generated on our innovative technology platform. we take o
